Navigation Links
Bionovo to Present at Canaccord Adams Global Growth Conference
Date:8/8/2008

EMERYVILLE, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced today that Tom Chesterman, SVP and CFO of Bionovo, will be presenting at the Canaccord Adams 28th Annual Global Growth Conference in Boston. The presentation is scheduled to begin at 8:00 AM ET on Wednesday, August 13, 2008 at the InterContinental Boston Hotel.

The presentation will be webcast and can be viewed on Bionovo's website at http://webcasts.bionovo.com. A webcast replay will become available approximately 1 hour after the presentation ends and will continue to be accessible for 90 days via Bionovo's website.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-lo
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bionovo Reports Second Quarter 2008 Financial Results
2. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
3. Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
4. Bionovo Reports First Quarter 2008 Financial Results
5. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
6. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
7. Louis Drapeau Joins Bionovos Board of Directors
8. George Butler Joins Bionovos Board of Directors
9. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
10. Bionovo Announces Third Quarter 2007 Financial Results
11. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, oral ... gallstones, today announced financial results for the period ended ... Summary: , Reported cash and cash equivalents totaling ... at December 31, 2013.  , Reported a net ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving ... today said it strongly supports legislation introduced in Congress ... Secretary of Health and Human Services to develop and ...
... Qutenza(TM) (NGX-4010)Identification of Impact of PHN and PDN ... /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: ... developing and commercializing novel pain management therapies, announced ... 61st Annual American Academy of Neurology (AAN) meeting ...
... N.J., April 29 Orchid Cellmark Inc., (Nasdaq: ... President and Chief Executive Officer of Orchid Cellmark, is scheduled ... Conference in New York City on Wednesday, May 13, 2008 ... overview and discuss the company,s recent and ongoing progress. A ...
Cached Biology Technology:Cord Blood America Supports Effort in Congress to Inform on Value of Umbilical Cord Blood Stem Cell Storage 2NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 2NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 3NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 4NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 5Orchid Cellmark to Present at the 2009 Bank of America Health Care Conference on May 13th 2Orchid Cellmark to Present at the 2009 Bank of America Health Care Conference on May 13th 3
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... shows that the age girls reach puberty is influenced by ... which parent contributes the gene. This is the first ... after birth and details of this study were published today ... first period, known as menarche, is a marker for the ... the onset of menses varies between girls, is an inherited ...
(Date:7/25/2014)... molecular testing panel developed at UPMC greatly increases ... for patients with thyroid nodules and cancer, report ... (UPCI), partner with UPMC CancerCenter., The test, available ... diagnostic testing agencies, improved the chances of patients ... according to the study published this month in ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... study shows that personal values that people refuse to disavow, ... in the brain than those values that are willingly sold. ... whether it,s a strong religious belief, a national identity ... process," says Gregory Berns, director of the Center for Neuropolicy ...
... Doctors and researchers of Hospital del Mar and ... describing a new pharmacological resistance to cancer. This new ... (epidermal growth factor receptor) causing resistance to treatment using ... attacks the EGFR. The study proves that, both ...
... RIKEN SPring-8 Center in Harima, Japan have clarified the ... a bacterial enzyme that offers clues on the origins ... importance to fundamental science, the findings provide key insights ... greenhouse gas hundreds of times more potent than carbon ...
Cached Biology News:The price of your soul: How the brain decides whether to 'sell out' 2The price of your soul: How the brain decides whether to 'sell out' 3Identified a cause of resistance to colon cancer treatment 2New study sheds light on evolutionary origin of oxygen-based cellular respiration 2
... genomes has allowed the development of the ... The S. enterica Typhimurium (strain LT2) genome ... 4,440 ORFs) and a plasmid, pSLT (93,939 ... have been designed to amplify all putative ...
... Twister II Microplate Handler is a ... for integrating BioTeks washers, readers and ... microplate capacity, ultimate flexibility and intuitive ... adding capacity to single devices or ...
XPLAC (S-17)...
Request Info...
Biology Products: